Comparison of fluorodeoxyglucose positron emission tomography and ‘conventional diagnostic procedures’ for the detection of distant metastases in breast cancer patients

Nuclear Medicine Communications

Volumn 23, Issue 9, 2002, Pages 857-864

  Dose, J ^a   Bleckmann, C ^a   Bachmann, S ^a   Bohuslavizki, K H ^a   Berger, J ^b   Jenicke, L ^b   Habermann, C R ^b   Janicke F ^b  

^a Nuclear Medicine   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Bone scintigraphy; Breast cancer; FDG PET; Metastases; Ultrasound of the abdomen; X ray of the chest

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER LOCALIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; THORAX RADIOGRAPHY; ULTRASOUND;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DIAGNOSTIC IMAGING; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036736484     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200209000-00009     Document Type: Article

References (21)

1. Smith RA, Guisti R. The epidemiology of breast cancer. In: Basset LW, Jackson VP, eds. Diagnosis of diseases of the breast. Philadelphia: Saunders, 1996: 293-316.
2. Dearnaley DP, Ormerod MG, Sloane JP. Micrometastases in breast cancer: long term follow-up of the first patient cohort. Eur J Cancer 1991; 27: 236-239.
3. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-648.
4. Avril N, Schelling M, Dose J, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitation. J Clin Oncol 2000; 18: 3495-3502.
5. Avril N, Dose J, Jänicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 88: 1204-1209.
6. Dose J, Avril N, Graeff H, Jänicke F. Positron emission tomography for diagnosis of breast tumors. Onkologie 1997; 20: 190-195.
7. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-3925.
8. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomography imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 1: 27-34.
9. Bleckmann C, Buchert R, Schulte U, et al. Onko-PET: Bildanalyse mittels Monitor versus standardisierter Filmdokumentation. Nuklearmedizin 1999; 38: 56-60.
10. Schirrmeister H, Kühn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28: 351-358.
11. Bender H, Kirst J, Palmedo H, et al. Value of 18-fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Research 1997; 17: 1687-1692.
12. Meissner WA, Warren S. Sites of metastases at autopsy. In: Anderson WA, ed. Pathology. St. Louis: Mosby, 1971: 538.
13. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-187.
14. Cody HS, Urban JA. Internal mammary node status: A major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 1995; 2: 32-37.
15. Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999; 210: 807-814.
16. Eubank WB, Mankoff DA, Takasugi J, et al. Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001; 19: 3516-3523.
17. Steinert H-C, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG-PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-446.
18. m-MDP bone scintigraphy. Nucl Med Commun 2001; 22: 875-879.
19. 18FDG PET. Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-3379.
20. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337: 949-955.
21. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997; 337: 956-962.